Division of Shire PLC
Latest From Baxalta Inc.
Celgene will pursue "high-impact" indications using Vividion's proteomics technology, while Magenta will use Heidelberg's technology to try to optimize bone marrow transplants.
Potential upheavals in the hemophilia market bring uncertainty for Shire and Bayer, with executives likely to be quizzed on how they can retain market share during upcoming Q4 results calls. Scrip’s final earnings preview highlights the key challenges for large companies reporting at the tail-end of the earnings season.
Shire explains why it is seeking preliminary injunction against Genentech; National Hemophilia Foundation and Hemophilia Federation of America decline to take position on dispute.
- Gene Therapy, Cell Therapy
- Large Molecule
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Neurology, Nervous System
- Baxter BioScience
- North America
- Parent & Subsidiaries
- Shire PLC
- Senior Management
Ludwig N Hantson, PhD, Pres. & CEO
Robert J Hombach, EVP, CF & COO
John J Orloff, MD, EVP, Head, R&D & CSO
- Contact Info
Phone: (224) 940-2000
One Baxter Pkwy.
Deerfield, IL 60015
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.